{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:54:27Z","timestamp":1780048467880,"version":"3.53.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40265-024-02026-3","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T04:01:43Z","timestamp":1714795303000},"page":"587-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bimekizumab: A Review in Psoriatic Arthritis"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3514-6918","authenticated-orcid":false,"given":"Tina","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"5","key":"2026_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2026_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2026_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-017-3908-y","volume":"37","author":"F Mahmood","year":"2018","unstructured":"Mahmood F, Coates LC, Helliwell PS. Current concepts and unmet needs in psoriatic arthritis. Clin Rheumatol. 2018;37(2):297\u2013305.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2026_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2026_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","volume":"33","author":"J Reis","year":"2019","unstructured":"Reis J, Vender R, Torres T. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs. 2019;33(4):391\u20139.","journal-title":"BioDrugs"},{"issue":"4","key":"2026_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","volume":"17","author":"L Costa","year":"2017","unstructured":"Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D. 2017;17(4):509\u201322.","journal-title":"Drugs R D."},{"key":"2026_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.","journal-title":"Front Immunol"},{"issue":"4","key":"2026_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2026_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jaci.2023.03.035","volume":"152","author":"S Cole","year":"2023","unstructured":"Cole S, Manghera A, Burns L, et al. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. J Allergy Clin Immunol. 2023;152(3):783\u201398.","journal-title":"J Allergy Clin Immunol"},{"key":"2026_CR10","unstructured":"UCB Pharma S.A. Bimzelx (bimekizumab) 160 mg solution for injection in pre-filled pen or syringe: EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx. Accessed 20 Mar 2024."},{"key":"2026_CR11","unstructured":"UCB Pharma Ltd. Bimzelx (bimekizumab) 160 mg solution for injection in pre-filled pen: UK summary of product characteristics. 2024. https:\/\/products.mhra.gov.uk\/product\/?product=BIMZELX%20160%20MG%20SOLUTION%20FOR%20INJECTION%20IN%20PRE-FILLED%20PEN. Accessed 20 Mar 2024."},{"key":"2026_CR12","unstructured":"UCB Pharma Ltd. Bimzelx (bimekizumab) 160 mg solution for injection in pre-filled syringe: UK summary of product characteristics. 2024. https:\/\/products.mhra.gov.uk\/product\/?product=BIMZELX%20160%20MG%20SOLUTION%20FOR%20INJECTION%20IN%20PRE-FILLED%20SYRINGE. Accessed 20 Mar 2024."},{"key":"2026_CR13","unstructured":"UCB Japan Co. Ltd. Bimzelx (bimekizumab): Japanese prescribing information. 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/820110_3999464G1020_1_03. Accessed 20 Mar 2024."},{"issue":"5","key":"2026_CR14","first-page":"545","volume":"156","author":"C Rodr\u00edguez-Cerdeira","year":"2021","unstructured":"Rodr\u00edguez-Cerdeira C, Gonz\u00e1lez-Cesp\u00f3n JL, Mart\u00ednez-Herrera E, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Ital J Dermatol Venerol. 2021;156(5):545\u201357.","journal-title":"Ital J Dermatol Venerol."},{"issue":"4","key":"2026_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjd.20827","volume":"186","author":"R Oliver","year":"2022","unstructured":"Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652\u201363.","journal-title":"Br J Dermatol"},{"issue":"10370","key":"2026_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25\u201337.","journal-title":"Lancet"},{"issue":"10370","key":"2026_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38\u201348.","journal-title":"Lancet"},{"issue":"10222","key":"2026_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","volume":"395","author":"CT Ritchlin","year":"2020","unstructured":"Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427\u201340.","journal-title":"Lancet"},{"issue":"1","key":"2026_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003855","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Landewe R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024;10(1):e003855.","journal-title":"RMD Open"},{"issue":"11","key":"2026_CR20","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1136\/ard-2023-224431","volume":"82","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-naive patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023;82(11):1404\u201314.","journal-title":"Ann Rheum Dis"},{"key":"2026_CR21","doi-asserted-by":"crossref","unstructured":"Merola J, Mease P, Deodhar A, et al. Bimekizumab impact on core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies [abstract no. 1433]. Arthritis Rheumatol. 2023;75(Suppl 9).","DOI":"10.1093\/rheumatology\/keae163.210"},{"key":"2026_CR22","doi-asserted-by":"crossref","unstructured":"McInnes I, Mease P, Tanaka Y, et al. Bimekizumab efficacy and safety in biologic DMARD-na\u00efve patients with psoriatic arthritis was consistent with or without methotrexate: 52-week results from the phase 3 active\u2011reference study BE OPTIMAL [abstract no. POS1537 plus poster]. Ann Rheum Dis. 2023;82(Suppl 1):1133\u20134.","DOI":"10.1136\/annrheumdis-2023-eular.1694"},{"key":"2026_CR23","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Asahina A, Merola JF, et al. Bimekizumab improves joint measures in patients with active psoriatic arthritis and moderate or severe psoriasis: pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE [abstract no. 43024]. J Am Acad Dermatol. 2023;89(3 Suppl):AB128.","DOI":"10.1016\/j.jaad.2023.07.513"},{"key":"2026_CR24","doi-asserted-by":"crossref","unstructured":"Tillett W, Merola J, Tanaka Y, et al. Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drug-naive patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, active-reference study [abstract no. POS1534 plus poster]. Ann Rheum Dis. 2023;82(Suppl 1):1130\u20131.","DOI":"10.1136\/annrheumdis-2023-eular.1667"},{"issue":"12","key":"2026_CR25","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/art.42280","volume":"74","author":"LC Coates","year":"2022","unstructured":"Coates LC, McInnes IB, Merola JF, et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a phase IIb randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022;74(12):1959\u201370.","journal-title":"Arthritis Rheumatol"},{"key":"2026_CR26","unstructured":"Sandal M. EULAR PsA recommendations update emphasizes safety, nonmusculoskeletal manifestations. 2023. https:\/\/www.medscape.com\/viewarticle\/993015?form=fpf. Accessed 20 Mar 2024."},{"issue":"2","key":"2026_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/1744666X.2023.2277266","volume":"20","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Shaw S. Bimekizumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2024;20(2):155\u201368.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"2026_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"2026_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341.","journal-title":"N Engl J Med"},{"issue":"10273","key":"2026_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487\u201398.","journal-title":"Lancet"},{"key":"2026_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead705","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Gladman DD, Merola JF, et al. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2024. https:\/\/doi.org\/10.1093\/rheumatology\/kead705.","journal-title":"Rheumatology (Oxford)"},{"key":"2026_CR32","unstructured":"Eli Lilly and Company (Ireland) Ltd. Taltz (ixekizumab): summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taltz. Accessed 20 Mar 2024."},{"key":"2026_CR33","unstructured":"Novartis Europharm Ltd. Cosentyx (secukinumab): summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cosentyx. Accessed 20 Mar 2024."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02026-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02026-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02026-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T18:17:40Z","timestamp":1718907460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02026-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02026-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"19 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tina Nie and Matt Shirley are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}